Abstract
Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 203-214 |
| Number of pages | 12 |
| Journal | Therapeutic Advances in Urology |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2016 |
Keywords
- immunotherapy
- NMIBC
- urothelial carcinoma
ASJC Scopus subject areas
- Urology
Fingerprint
Dive into the research topics of 'Novel immunotherapeutic approaches to the treatment of urothelial carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS